InnoCare Pharma Ltd Intrinsic Valuation and Fundamental Analysis - InnoCare Pharma Ltd - Alpha Spread

InnoCare Pharma Ltd
SSE:688428

Watchlist Manager
InnoCare Pharma Ltd Logo
InnoCare Pharma Ltd
SSE:688428
Watchlist
Price: 11.33 CNY -2.16% Market Closed
Market Cap: 9.6B CNY
Have any thoughts about
InnoCare Pharma Ltd?
Write Note

Intrinsic Value

InnoCare Pharma Ltd's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one InnoCare Pharma Ltd stock under the Base Case scenario is 4.11 CNY. Compared to the current market price of 11.33 CNY, InnoCare Pharma Ltd is Overvalued by 64%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
4.11 CNY
Overvaluation 64%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
InnoCare Pharma Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for InnoCare Pharma Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about InnoCare Pharma Ltd?
Bearish
Neutral
Bullish

Fundamental Analysis

Summary

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Wall St Estimates
Price Target
Loading
Revenue Forecast
Operating Income Forecast
Earnings Forecast
No Indicators Selected
Select Indicators
Investor Returns
Shareholder Yield
Dividend Safety
Dividend Yield
Dividend Payout Ratio
Buyback Yield
Debt Paydown Yield
No Indicators Selected
Select Indicators
Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about InnoCare Pharma Ltd

Provide an overview of the primary business activities
of InnoCare Pharma Ltd.

What unique competitive advantages
does InnoCare Pharma Ltd hold over its rivals?

What risks and challenges
does InnoCare Pharma Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for InnoCare Pharma Ltd.

Provide P/S
for InnoCare Pharma Ltd.

Provide P/E
for InnoCare Pharma Ltd.

Provide P/OCF
for InnoCare Pharma Ltd.

Provide P/FCFE
for InnoCare Pharma Ltd.

Provide P/B
for InnoCare Pharma Ltd.

Provide EV/S
for InnoCare Pharma Ltd.

Provide EV/GP
for InnoCare Pharma Ltd.

Provide EV/EBITDA
for InnoCare Pharma Ltd.

Provide EV/EBIT
for InnoCare Pharma Ltd.

Provide EV/OCF
for InnoCare Pharma Ltd.

Provide EV/FCFF
for InnoCare Pharma Ltd.

Provide EV/IC
for InnoCare Pharma Ltd.

Show me price targets
for InnoCare Pharma Ltd made by professional analysts.

What are the Revenue projections
for InnoCare Pharma Ltd?

How accurate were the past Revenue estimates
for InnoCare Pharma Ltd?

What are the Net Income projections
for InnoCare Pharma Ltd?

How accurate were the past Net Income estimates
for InnoCare Pharma Ltd?

What are the EPS projections
for InnoCare Pharma Ltd?

How accurate were the past EPS estimates
for InnoCare Pharma Ltd?

What are the EBIT projections
for InnoCare Pharma Ltd?

How accurate were the past EBIT estimates
for InnoCare Pharma Ltd?

Compare the revenue forecasts
for InnoCare Pharma Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of InnoCare Pharma Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of InnoCare Pharma Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of InnoCare Pharma Ltd compared to its peers.

Compare the P/E ratios
of InnoCare Pharma Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing InnoCare Pharma Ltd with its peers.

Analyze the financial leverage
of InnoCare Pharma Ltd compared to its main competitors.

Show all profitability ratios
for InnoCare Pharma Ltd.

Provide ROE
for InnoCare Pharma Ltd.

Provide ROA
for InnoCare Pharma Ltd.

Provide ROIC
for InnoCare Pharma Ltd.

Provide ROCE
for InnoCare Pharma Ltd.

Provide Gross Margin
for InnoCare Pharma Ltd.

Provide Operating Margin
for InnoCare Pharma Ltd.

Provide Net Margin
for InnoCare Pharma Ltd.

Provide FCF Margin
for InnoCare Pharma Ltd.

Show all solvency ratios
for InnoCare Pharma Ltd.

Provide D/E Ratio
for InnoCare Pharma Ltd.

Provide D/A Ratio
for InnoCare Pharma Ltd.

Provide Interest Coverage Ratio
for InnoCare Pharma Ltd.

Provide Altman Z-Score Ratio
for InnoCare Pharma Ltd.

Provide Quick Ratio
for InnoCare Pharma Ltd.

Provide Current Ratio
for InnoCare Pharma Ltd.

Provide Cash Ratio
for InnoCare Pharma Ltd.

What is the historical Revenue growth
over the last 5 years for InnoCare Pharma Ltd?

What is the historical Net Income growth
over the last 5 years for InnoCare Pharma Ltd?

What is the current Free Cash Flow
of InnoCare Pharma Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for InnoCare Pharma Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
InnoCare Pharma Ltd

Balance Sheet Decomposition
InnoCare Pharma Ltd

Current Assets 9.3B
Cash & Short-Term Investments 9.1B
Receivables 144.6m
Other Current Assets 101.4m
Non-Current Assets 1B
Long-Term Investments 11.7m
PP&E 696.5m
Intangibles 276.3m
Other Non-Current Assets 44.6m
Current Liabilities 2.1B
Accounts Payable 118.6m
Accrued Liabilities 57m
Other Current Liabilities 1.9B
Non-Current Liabilities 664m
Long-Term Debt 35.4m
Other Non-Current Liabilities 628.6m
Efficiency

Earnings Waterfall
InnoCare Pharma Ltd

Revenue
625.4m CNY
Cost of Revenue
-143.4m CNY
Gross Profit
482m CNY
Operating Expenses
-1.2B CNY
Operating Income
-730.9m CNY
Other Expenses
-155.7m CNY
Net Income
-886.6m CNY

Free Cash Flow Analysis
InnoCare Pharma Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

InnoCare Pharma Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Negative 1-Year Revenue Growth
Negative ROE
28/100
Profitability
Score

InnoCare Pharma Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

InnoCare Pharma Ltd's solvency score is 73/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
73/100
Solvency
Score

InnoCare Pharma Ltd's solvency score is 73/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
InnoCare Pharma Ltd

Wall Street analysts forecast InnoCare Pharma Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for InnoCare Pharma Ltd is 14.64 CNY with a low forecast of 14.14 CNY and a high forecast of 15.44 CNY.

Lowest
Price Target
14.14 CNY
25% Upside
Average
Price Target
14.64 CNY
29% Upside
Highest
Price Target
15.44 CNY
36% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for InnoCare Pharma Ltd?

Click here to dive deeper.

Shareholder Yield

Current shareholder yield for InnoCare Pharma Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Want to learn more about InnoCare Pharma Ltd dividends, buybacks, and debt paydown yield?

Click here to dive deeper.

Price
InnoCare Pharma Ltd

1M 1M
+16%
6M 6M
+14%
1Y 1Y
+17%
3Y 3Y
+21%
5Y 5Y
+21%
10Y 10Y
+21%
Annual Price Range
11.33
52w Low
7.3
52w High
11.78
Price Metrics
Average Annual Return 58.52%
Standard Deviation of Annual Returns
N/A
Max Drawdown -56%
Shares Statistics
Market Capitalization 9.6B CNY
Shares Outstanding 844 306 335
Percentage of Shares Shorted
N/A

Competitive Landscape

Profile

InnoCare Pharma Ltd Logo
InnoCare Pharma Ltd

Country

China

Industry

Biotechnology

Market Cap

9.6B CNY

Dividend Yield

0%

Description

InnoCare Pharma Ltd. is a clinical-stage biopharmaceutical company. The company is headquartered in Beijing, Beijing. The company went IPO on 2020-03-23. The firm discovers, develops and commercializes potentially best-in-class and first-in-class drugs for the treatment of cancer and autoimmune diseases. The firm builds a fully integrated biopharmaceutical platform with strong in-house research and development capabilities, including drug target identification and verification, preclinical evaluation, clinical trial design and execution, drug manufacturing and quality control, and commercialization.

Contact

BEIJING
Beijing
Building 8, No. 8 Shengmingyuan Road, Zhongguancun Science Park, Changping District
www.innocarepharma.com

IPO

2020-03-23

Employees

531

Officers

See Also

Discover More
What is the Intrinsic Value of one InnoCare Pharma Ltd stock?

The intrinsic value of one InnoCare Pharma Ltd stock under the Base Case scenario is 4.11 CNY.

Is InnoCare Pharma Ltd stock undervalued or overvalued?

Compared to the current market price of 11.33 CNY, InnoCare Pharma Ltd is Overvalued by 64%.

Back to Top